Biomarkers of Skeletal Muscle Preservation During Major Body-Composition Changes

Abstract

Preserving skeletal muscle mass is a crucial goal during periods of major body-composition changes, such as those induced by weight loss, chronic disease, aging, or intense physical training. The identification and validation of reliable biomarkers that reflect muscle preservation have significant clinical implications, enabling early detection of muscle loss, guiding therapeutic interventions, and improving patient outcomes. This review synthesizes the current scientific evidence on established and emerging biomarkers for skeletal muscle preservation, focusing on molecular, biochemical, and imaging modalities. The article highlights their pathophysiological relevance, diagnostic utility, limitations, and the latest advances that may shape future clinical practice.

Introduction

Major body-composition changes, such as those seen in conditions like obesity, cachexia, sarcopenia, metabolic syndrome, and after bariatric surgery, often pose a threat to skeletal muscle integrity. Loss of skeletal muscle mass and function, irrespective of fat mass dynamics, is consistently associated with worse outcomes across a spectrum of diseases, ranging from increased morbidity and mortality to impaired quality of life and reduced physical independence. Accordingly, there is a growing emphasis on the development and implementation of biomarkers that can accurately monitor skeletal muscle preservation. These biomarkers serve not only as tools for diagnosis and risk stratification but also as surrogate endpoints for therapeutic efficacy in both clinical and research settings.

Epidemiology / Disease Burden

Skeletal muscle wasting is prevalent in diverse populations undergoing major body-composition changes. Sarcopenia affects up to 50% of individuals over age 80 and is frequently encountered in chronic disease states, such as chronic heart failure, chronic obstructive pulmonary disease (COPD), cancer, and chronic kidney disease. In the context of obesity management, aggressive caloric restriction without appropriate interventions can result in significant muscle loss, with studies reporting up to 25% of total weight lost being lean tissue. The clinical burden of muscle loss manifests as increased falls, frailty, hospitalization rates, and mortality, reinforcing the need for vigilant assessment and preservation strategies.

Pathophysiology

Skeletal muscle mass is regulated by a balance between anabolic and catabolic signaling pathways. Anabolic stimuli, including insulin, growth hormone, and resistance exercise, promote protein synthesis via the PI3K-Akt-mTOR pathway. Conversely, catabolic factors such as inflammatory cytokines (TNF-α, IL-6), glucocorticoids, and myostatin upregulate the ubiquitin-proteasome and autophagy-lysosome systems, accelerating protein degradation. During significant body-composition changes, the disruption of this balance, often compounded by systemic inflammation, oxidative stress, hormonal alterations, and reduced mechanical loading, precipitates muscle loss. Biomarkers reflecting these molecular events can offer mechanistic insight and enable real-time monitoring of muscle preservation or depletion.

Risk Factors

Risk factors for skeletal muscle loss during major body-composition changes include advanced age, chronic illness, prolonged immobility, malnutrition, systemic inflammation, and inadequate protein intake. Specific scenarios, such as rapid weight loss through bariatric surgery or aggressive dietary interventions, further amplify the risk, especially when not accompanied by resistance training or adequate nutritional support. Genetic predispositions, hormonal imbalances (e.g., low testosterone or estrogen), and comorbidities such as diabetes or renal insufficiency also contribute to an individual's vulnerability to muscle wasting.

Clinical Features

Clinically, muscle wasting may present subtly as decreased strength, fatigue, reduced exercise tolerance, and impaired functional performance. Objective findings include reduced muscle mass on physical exam or imaging, diminished grip strength, and slower gait speed. In severe cases, the loss of muscle mass leads to overt frailty, increased susceptibility to falls, delayed wound healing, and prolonged recovery from illness or surgery. Early detection, preferably before functional impairment becomes evident, hinges on sensitive and specific biomarkers that can track changes in muscle status over time.

Diagnosis

Traditional diagnostic approaches rely on anthropometric measurements, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), and computed tomography (CT) or magnetic resonance imaging (MRI) for quantifying muscle mass. Biochemical markers, including serum creatinine, creatine kinase, and 3-methylhistidine, have been explored but lack specificity and sensitivity in isolation. Recent advances have spotlighted circulating microRNAs (myomiRs), myostatin, follistatin, and inflammatory cytokines as promising molecular biomarkers. Additionally, urinary titin fragments and novel proteomic/metabolomic signatures are under investigation for their potential to reflect dynamic changes in muscle status, particularly in acute care or critical illness scenarios.

Treatment & Management

Muscle preservation strategies during major body-composition change encompass nutritional optimization (adequate protein and leucine intake), resistance exercise, and pharmacological interventions targeting anabolic pathways or inhibiting catabolic signals. Early identification of individuals at risk, guided by reliable biomarkers, enables timely initiation of such interventions. Tailoring therapy based on biomarker trajectories may improve outcomes, reduce muscle loss, and enhance functional recovery, especially in high-risk populations such as the elderly, cancer patients, and those undergoing major surgery.

Recent Advances / Emerging Therapies

The advent of high-throughput omics technologies has accelerated the discovery of novel biomarkers for skeletal muscle preservation. Circulating myomiRs (e.g., miR-1, miR-133a, miR-206) and exosomal proteins are emerging as minimally invasive markers linked to muscle health. Machine learning approaches integrating multi-omics data with imaging and functional assessments show promise for individualized risk prediction and monitoring. Therapeutically, agents targeting myostatin, activin receptor signaling, and selective androgen receptor modulators (SARMs) are under clinical investigation for their muscle-sparing effects. These advances may soon translate into more personalized, biomarker-driven care pathways for muscle preservation.

Guideline Recommendations

International guidelines, such as those from the European Working Group on Sarcopenia in Older People (EWGSOP) and the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD), recommend a combination of functional (e.g., grip strength, gait speed) and quantitative (DXA, BIA) assessments for diagnosing muscle loss. While no single biomarker is universally endorsed, there is increasing support for the integration of biochemical and molecular markers with clinical and imaging data to improve diagnostic accuracy and guide therapy. Ongoing research is expected to refine these recommendations as novel biomarkers are validated in diverse clinical settings.

Conclusion

The preservation of skeletal muscle during major body-composition changes is a cornerstone of optimal clinical care, impacting outcomes across a wide spectrum of diseases and interventions. Biomarkers play a critical role in the early detection, risk stratification, and monitoring of muscle mass, offering mechanistic insight and guiding targeted interventions. As the field advances, the integration of molecular, proteomic, and imaging biomarkers with functional assessments will likely transform clinical practice, enabling more precise and effective strategies for muscle preservation and improved patient outcomes.